The order with no date on it
Here is the procedural state of play. The FDA's proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list published May 1. The comment period, extended once, closed July 30, 2026. Our H2 metabolic calendar originally carried the June close date; the extension superseded it, and the queue has now cleared either way. What remains is the part with no date: the final order can publish any week, with no advance notice, and it will arrive attached to a full news cycle.
That combination, certain event, unknowable date, is exactly what run-books are for. The programs that handle the order well will not be the ones with the smartest people on the day. They will be the ones that wrote everything down in August and spent the day filling in blanks. This post is that run-book: what to have prewritten, what to execute hour by hour, and the specific language patterns that turned into warning letters for other operators this year.
The Real 2026 Peptide Timeline
Removal from Category 2 is the first gate, not the last. The path from April 2026 to a legally compoundable peptide runs through the PCAC meeting, an FDA determination, and 503A Bulks List inclusion.
- 1April 22, 2026Complete
Removed from Category 2
BPC-157, TB-500, KPV, MOTs-c, Semax, Epitalon, and DSIP exit the FDA's significant-safety-concerns list. Compounding still not authorized.
- 2July 9, 2026Upcoming
Public comment deadline
Final day to submit comments to docket FDA-2025-N-6895. Comments after this date are not presented to the committee.
- 3July 23-24, 2026Upcoming
PCAC meeting at White Oak
Pharmacy Compounding Advisory Committee reviews and votes on adding peptides to the 503A Bulks List. Day 1 covers BPC-157, KPV, TB-500, MOTs-c. Day 2 covers DSIP, Semax, Epitalon.
- 4Post-meetingPending FDA
FDA determination
FDA reviews the PCAC recommendations and publishes a determination, typically through a notice or proposed rule. Usually months, not days.
- 5503A Bulks ListPending FDA
Compounding becomes legal
Once a peptide is formally included, licensed 503A pharmacies may compound for individual patients with a valid prescription, subject to the rest of the framework.
The 72 hours at a glance
| Window | Move | Asset to have prewritten |
|---|---|---|
| Hours 0 to 2 | Read the order itself: effective date, wind-down provisions, scope | A one-page internal brief template |
| Hours 2 to 6 | Confirm branded supply and routing with pharmacy partners | Partner contact sheet and confirmation checklist |
| Hours 6 to 24 | Send the patient email | The email below, with blanks filled |
| Hours 12 to 36 | Swap the pricing page and program copy | A staged branded-era pricing page |
| Hours 12 to 36 | Publish the day-one blog post | An 80%-written explainer with outcome blanks |
| Hours 24 to 48 | Retrain support on the macro pack | Approved macros for the ten predictable questions |
| Hours 48 to 72 | Sweep ads, landing pages, intake, and checkout copy | Your claims inventory from the last compliance pass |
One discipline governs the whole board: nothing ships that was not reviewed in calm conditions. The day the order publishes is a fill-in-the-blanks day, not a writing day.
Hours 0 to 6: read the order, then call your pharmacies
Resist the urge to react to coverage. Headlines will compress a technical Federal Register document into "FDA bans compounded Ozempic," and every operator who communicates from the headline instead of the text will say something wrong. Assign one person to read the actual order and complete the one-page brief: what is excluded, effective when, under what wind-down provisions, and what is explicitly out of scope. Every downstream asset inherits its blanks from this page.
Then confirm supply before patients feel anything. If your program already runs on branded rails, this is a verification call: inventory posture, expected fill times under a demand spike, failover routing if a partner queues up. If any volume still touches compounded supply, this is the moment your wind-down plan stops being theoretical. The architecture for multi-pharmacy failover and branded routing is in Pharmacy Routing Architecture for Telehealth, and the strategic case you should have already made to yourself is in The Branded GLP-1 Era.
Hours 6 to 24: the patient email
Patients will see the news before most programs email them. The winning message is fast, specific, and boring, in the best sense: it answers "what happens to me" in the first two sentences. Prewrite it now:
Subject: The FDA's compounding order: what changes for you, and what does not
Hi [FIRST NAME],
You may have seen news that the FDA finalized its order on large-scale compounded GLP-1 medications. Here is exactly what it means for your care: [ONE SENTENCE: nothing changes today / your medication transitions on DATE].
Your care team, your check-ins, and your refill schedule stay the same. [IF TRANSITIONING: Before EFFECTIVE DATE, we will move you to branded MEDICATION, supplied through our pharmacy partners, at PRICE per month. You do not need to do anything today; we will confirm each step in your portal.]
If you have questions, reply here or message us in your portal. A clinician will answer within [SLA].
Five blanks, one send. Note what the template does not do: no drama, no editorializing about the FDA, no sales pitch stapled to a regulatory notice. Continuity is the product; the email should sound like it.
Hours 12 to 36: the public surfaces
The pricing page. Stage the branded-era version now, priced and reviewed, so the swap is a deploy rather than a redesign. If compounded offers appear anywhere in your funnel, ads, landing pages, comparison tables, checkout, they all move in the same window. A pricing page that contradicts the day's news reads as either negligence or deception, and screenshots outlive both.
The day-one post. Fast, dated, structured coverage of a regulatory event is the single most reliable way to earn AI-assistant citations that persist for months, a pattern we documented in Generative Engine Optimization for Telehealth. Prewrite the explainer now: what the order says, what it means for patients on compounded medication, what the branded options cost, what happens next. Leave blanks for the effective dates and any surprises in the final text, and publish within hours, not days.
Support macros. The questions are predictable: am I losing my medication, will my price change, is compounded medication dangerous now, can I stockpile, when do I switch. Write the answers in calm conditions, get clinical sign-off, and load them where agents actually work.
What not to say
The FDA ran two warning-letter waves against telehealth GLP-1 marketing this year: roughly 30 companies in the February wave and another 25 in June. The cited patterns are consistent, and order day is the worst possible day to repeat them, because regulator and press attention on the category will never be higher. From the letters, and from what teams changed after the crackdown:
- Never imply a compounded product is FDA approved, a generic, or "the same medication" as a branded drug. Equivalence framing is the most-cited violation.
- Do not obscure who compounds or supplies a product behind house branding.
- Do not spin the order itself: no "FDA cracks down on cheap alternatives, but we still have supply" urgency plays, and no implying the FDA endorsed your branded offering.
- Do not speculate beyond the order's text on timelines or enforcement, in either direction.
- Do not leave old compounded claims live anywhere while the news cycle points at the category. The 72-hour sweep exists because archived ad variants and forgotten landing pages get screenshotted too.
The safe register is quotation and plain description: what the order says, when it takes effect, what your program offers, what it costs.
FAQ
What is the FDA's 503B final order on GLP-1s? It is the final version of the FDA's proposal, published May 1, 2026, to remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list, which would end large-scale outsourcing-facility compounding of those medications. The comment period closed July 30, 2026, and the final order is the remaining step.
When will the final order publish? There is no announced date. With comments closed, the order can publish any week, so telehealth programs should treat readiness as a standing state rather than a scheduled project.
What should a telehealth program do first when the order drops? Read the order's actual text for effective dates and wind-down provisions before reacting to headlines, confirm branded supply with pharmacy partners, and send a prewritten patient email that answers "what happens to me" within the first day.
What compounded GLP-1 marketing claims trigger FDA warning letters? Claims implying compounded products are FDA approved, generic versions, or equivalent to branded drugs, and branding that obscures who actually compounds or supplies the product. The February and June 2026 warning-letter waves, roughly 30 and 25 companies respectively, cited these patterns repeatedly.